Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Impact BioMedical Inc. IBO NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
17/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Impact BioMedical Inc. (IBO) is a Biotechnology company in the Healthcare sector, currently trading at $0.66. It has a SharesGrow Score of 16/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: IBO trades at a trailing Price-to-Earnings (P/E) of -1.8 (S&P 500 average ~25).

Financials: revenue is $32,000, +9.5%/yr average growth. Net income is $12M (loss), growing at -189.3%/yr. Net profit margin is -36993.8% (negative). Gross margin is -4803.1% (-4903.1 pp trend).

Balance sheet: total debt is $0 against $13M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.35 (tight liquidity). Debt-to-assets is 0%. Total assets: $17M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

IBO SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IBO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
40/100
IBO: +9.5%/yr revenue is, -189.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet IBO: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 0.35 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
IBO: Net profit margin is -36993.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.362-1.95
Volume133.76K
Avg Volume (30D)4.51M
Market Cap$8.28M
Beta (1Y)6.38
Share Statistics
EPS (TTM)-0.38
Shares Outstanding$31.55M
IPO Date2024-09-16
Employees2
CEOFrank D. Heuszel
Financial Highlights & Ratios
Revenue (TTM)$32K
Gross Profit$-1.54M
EBITDA$-3.13M
Net Income$-11.84M
Operating Income$-4.27M
Total Cash$3K
Net Debt$-3K
Total Assets$17.41M
Price / Earnings (P/E)-1.7
Price / Sales (P/S)258.71
Analyst Forecast
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS45259L2051

Price Chart

Track all markets on TradingView
IBO
Impact BioMedical Inc. ↗  ·  NYSE
Healthcare • Biotechnology
0.36 52WK RANGE 1.95

People Also View

ELLO
ELLO
Ellomay Capital Ltd.
$24.37
-0.57%
 NBW
NBW
Neuberger Berman California Municipal Fund Inc.
$9.49
+0.11%
 NBO
NBO
Neuberger Berman New York Municipal Fund, Inc.
$8.48
+0.12%
 GRF
GRF
Eagle Capital Growth Fund, Inc.
$10.15
-1.93%
 NRSN
NRSN
NeuroSense Therapeutics Ltd.
$0.71
-0.11%
 CYCN
CYCN
Cyclerion Therapeutics, Inc.
$3.22
+11.42%
 BCLI
BCLI
Brainstorm Cell Therapeutics Inc.
$0.86
-0.21%
 TCRT
TCRT
Alaunos Therapeutics, Inc.
$2.99
+1.01%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message